GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (FRA:DU8) » Definitions » PB Ratio

Genetic Technologies (FRA:DU8) PB Ratio : 5.44 (As of Dec. 13, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Genetic Technologies PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-13), Genetic Technologies's share price is €0.049. Genetic Technologies's Book Value per Share for the quarter that ended in Jun. 2024 was €0.01. Hence, Genetic Technologies's PB Ratio of today is 5.44.

The historical rank and industry rank for Genetic Technologies's PB Ratio or its related term are showing as below:

FRA:DU8' s PB Ratio Range Over the Past 10 Years
Min: 0.41   Med: 3.02   Max: 23.21
Current: 2.79

During the past 13 years, Genetic Technologies's highest PB Ratio was 23.21. The lowest was 0.41. And the median was 3.02.

FRA:DU8's PB Ratio is ranked worse than
62.19% of 201 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.18 vs FRA:DU8: 2.79

During the past 12 months, Genetic Technologies's average Book Value Per Share Growth Rate was -85.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -61.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -23.10% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -23.40% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Genetic Technologies was 47.00% per year. The lowest was -61.20% per year. And the median was -9.30% per year.

Back to Basics: PB Ratio


Genetic Technologies PB Ratio Historical Data

The historical data trend for Genetic Technologies's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies PB Ratio Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.51 2.63 0.85 0.83 4.28

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2.83 - 4.28 -

Competitive Comparison of Genetic Technologies's PB Ratio

For the Diagnostics & Research subindustry, Genetic Technologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Technologies's PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's PB Ratio distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's PB Ratio falls into.



Genetic Technologies PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Genetic Technologies's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2024)
=0.049/0.009
=5.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Genetic Technologies  (FRA:DU8) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Genetic Technologies PB Ratio Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Technologies Business Description

Traded in Other Exchanges
Address
60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

Genetic Technologies Headlines

No Headlines